Van Looveren RX, radiologie BV
0735.850.611 · rovalta.com · 28/09/2026
ACTIVE
Van Looveren RX, radiologie BV
Financial year 2025 · Closed on 31/12/2025
Net result605 k €-1,8 %over 1 year
Gross margin832,5 k €-0,1 %over 1 year
Equity100 €-100,0 %over 1 year
Workforce0,0 ETP
Overview
Identity
Source · BCE/KBOVan Looveren RX, radiologie BV is a Private limited company incorporated in 2019. Its registered office is in Schilde.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0735.850.611
- Incorporation
- 08/10/2019
- Legal form
- Private limited company
- Registered office
- De Nachtegaal 42
2970 Schilde · FlandreSee on map - Contributed capital
- 100,00 €
- Latest accounts
- 31/12/2025
- Average workforce
- 0,0 ETP
Signals
ProfitablePositive cashflowPositive EBITDA
Financials
Source · NBB, 7 filingsTrend over 6 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 832,5 k € | -0.1% | 833,1 k € | +5.7% | 788,4 k € | +11.5% | 707,1 k € | +19.0% | 594,3 k € |
| EBITDA | 832 k € | -0.0% | 832 k € | +5.7% | 787,2 k € | +11.5% | 706,2 k € | +19.0% | 593,6 k € |
| Operating result | 807,3 k € | -0.8% | 814,2 k € | +5.6% | 771,2 k € | +11.7% | 690,8 k € | +19.5% | 578,1 k € |
| Net result | 605 k € | -1.8% | 616,1 k € | +5.4% | 584,5 k € | +12.8% | 518,3 k € | +19.6% | 433,6 k € |
| Balance sheet | |||||||||
| Equity | 100 € | -100.0% | 616,2 k € | +5.4% | 584,6 k € | +12.7% | 518,5 k € | -42.4% | 899,5 k € |
| Total assets | 610,9 k € | -8.3% | 665,9 k € | -19.5% | 826,9 k € | +16.5% | 710 k € | -32.4% | 1,1 M € |
| Cash | 8,7 k € | -89.2% | 80,6 k € | -73.4% | 303,2 k € | +49.0% | 203,6 k € | -64.8% | 579 k € |
| Debts | 610,2 k € | +1144% | 49,1 k € | -79.7% | 241,8 k € | +26.6% | 191 k € | +29.4% | 147,5 k € |
| Other | |||||||||
| Workforce | 0,0 ETP | 0,0 ETP | 0,0 ETP | – | – | ||||
Valuation
Indicative valuation
As an indication, this company is worth
between 5 M€ and 10 M€
See the valuationBoard of directors
Source · NBB, accounts to 31/12/20251 active
Active mandates
| Director | Mandates in this company | Period |
|---|---|---|
Kevin Van Looveren | Directorsince 08/10/2019 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 28/04/2026 | 29/04/2025 | 26/04/2024 | 28/06/2023 | 25/08/2022 | 29/07/2021 |
| General meeting | 24/04/2026 | 25/04/2025 | 26/04/2024 | 15/06/2023 | 29/04/2022 | 30/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 7 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 24/04/2026 | 28/04/2026 | Dutch | |
| Abridged model | 31/12/2024 | 25/04/2025 | 29/04/2025 | Dutch | |
| Abridged model | 31/12/2023 | 26/04/2024 | 26/04/2024 | Dutch | |
| Micro model | 31/12/2022 | 15/06/2023 | 28/06/2023 | Dutch | |
| Micro model | 31/12/2021 | 29/04/2022 | 25/08/2022 | Dutch | |
| Micro model | 31/12/2020 | 30/06/2021 | 29/07/2021 | Dutch | |
| Micro model | 31/12/2019 | 24/04/2020 | 15/05/2020 | Dutch |
Valuation
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 5 M€ and 10 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20251 active
Active mandates
| Director | Mandates in this company | Period |
|---|---|---|
Kevin Van Looveren | Directorsince 08/10/2019 |
Ownership and network
Looking for more information about this company?
Try for freePublications
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
Source · CBE, NBB annual accountsYear
Identity
Incorporation
Name
Registered office
Annual accounts
Filings6 filings
Mandates
Kevin Van Looveren
20192020202120222023202420252026
Van Looveren RX, radiologie BV
De Nachtegaal 42, 2970 SchildeAnselmostraat 56, 2018 Antwerp-2018
Director
CurrentPlanned, not yet servedEndedAccounts filedToday
Registered offices
Source · NBB annual accounts, CBE| Registered address | Period | Source |
|---|---|---|
| De Nachtegaal 42, 2970 SchildeCurrent | accounts 2024 → 2025 | Accounts 2025 · 2026-00091191 |
| Anselmostraat 56, 2018 Antwerp-2018 | accounts 2021 → 2023 | Accounts 2023 · 2024-00070866 |
Company names
Source · NBB annual accounts, CBE| Name | Period | Source |
|---|---|---|
| Van Looveren RX, radiologie BVCurrent | accounts 2021 → 2025 | Accounts 2025 · 2026-00091191 |
Events
- 2025Annual accounts 2025605 k €↓
- 2024Annual accounts 2024616,1 k €↑
- 2023Annual accounts 2023584,5 k €↑
- 2022Annual accounts 2022518,3 k €↑
- 2021Annual accounts 2021433,6 k €↑
- 2019Annual accounts 2019133,7 k €
- 08/10/2019IncorporationPrivate limited company